| 238 | 0 | 282 |
| 下载次数 | 被引频次 | 阅读次数 |
舍曲林作为临床广泛应用的强效选择性5-羟色胺再摄取抑制剂（SSRI），其稳态血药浓度在常规给药剂量下存在显著的个体差异。这种差异源于多因素，包括剂量、年龄、肝功能状态、合并用药情况以及遗传多态性等影响。本综述系统分析影响舍曲林血药浓度的关键因素（涵盖剂量、人口学特征、生理病理状态及药物相互作用等方面），旨在为临床制定个体化给药方案提供循证依据，以优化治疗效果并确保用药安全。
Abstract：As a potent and selective serotonin reuptake inhibitor(SSRI) widely used in clinical practice, sertraline has significant inter-individual differences in its steady-state plasma concentration under conventional doses. This difference stems from multifactorial effects, including dose, age, liver function status, concomitant medication status, and drug metabolism-related factors such as genetic polymorphisms. This review systematically analyzed the key factors affecting sertraline blood concentration(including dose, demographic characteristics, physiopathological status, and drug interactions), aiming to provide evidence-based basis for the clinical formulation of individualized dosing regimens, so as to optimize the treatment effect and ensure drug safety.
[1]裴丽,罗艳,李翔,等.舍曲林的临床应用新进展与合理用药[J].中国药房, 2015, 26(27):3886.
[2]中华医学会行为医学分会,中华医学会行为医学分会认知应对治疗学组.抑郁症治疗与管理的专家推荐意见(2022年)[J].中华行为医学与脑科学杂志, 2023, 32(3):19.
[3] MURPHY S E, CAPIT?O L P, GILES S L C, et al. The knowns and unknowns of SSRI treatment in young people with depression and anxiety:efficacy, predictors, and mechanisms of action[J].Lancet Psychiatry, 2021, 8(9):824.
[4]李岚.盐酸舍曲林片在青少年和老年人群中的应用[J].疾病监测与控制, 2023, 17(4):266.
[5] ALHADAB A A, BRUNDAGE R C. Population pharmacokinetics of sertraline in healthy subjects:a model-based meta-analysis[J].AAPS J, 2020, 22(4):73.
[6] CASTILLO C E C, GARIBAY S E M, SEGOVIA R D C M, et al. Population pharmacokinetics of sertraline in psychiatric and substance use disorders[J]. J Clin Pharmacol, 2024, 64(10):1267.
[7] MANDRIOLI R, MERCOLINI L, RAGGI M A. Evaluation of the pharmacokinetics, safety and clinical efficacy of sertraline used to treat social anxiety[J]. Expert Opin Drug Metab Toxicol, 2013,9(11):1495.
[8] POWELEITEA, ALDRICHSL, MARINLJ, et al.Pharmacogenetics of sertraline tolerability and response in pediatric anxiety and depressive disorders[J]. J Child Adolesc Psychopharmacol, 2019, 29(5):348.
[9] DEVANE C L, LISTON H L, MARKOWITZ J S. Clinical pharmacokinetics of sertraline[J]. Clin Pharmacokinet, 2002,41(15):1247.
[10]朱金芳,陈兆霓,刘滔滔,等.新型抗抑郁药血药浓度与临床疗效相关性的研究进展[J].中国临床新医学, 2020, 13(3):317.
[11]张惠兰,王磊,赵婷,等.抑郁症患儿体内盐酸舍曲林血浆谷浓度的影响因素分析[J].药物评价研究, 2024, 47(7):1619.
[12] HIEMKE C, BAUMANN P, BERGEMANN N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry:update 2011[J]. Pharmacopsychiatry, 2011, 44(6):195.
[13] SCHORETSANITIS G, PAULZEN M, UNTERECKER S, et al.TDM in psychiatry and neurology:a comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians[J].World J Biol Psychiatry, 2018, 19(3):162.
[14] MAURI M C, FIORENTINI A, CERVERI G, et al. Long-term efficacy and therapeutic drug monitoring of sertraline in major depression[J]. Hum Psychopharmacol, 2003, 18(5):385.
[15] SEPúLVEDA-LIZCANO L, ARENAS-VILLAMIZAR V V,JAIMES-DUARTE E B, et al. Metabolic adverse effects of psychotropic drug therapy:a systematic review[J]. Eur J Investig Health Psychol Educ, 2023, 13(8):1505.
[16] CHERMáM D, AHLNER J, BENGTSSON F, et al. Antidepressant drugs in children and adolescents:analytical and demographic data in a naturalistic, clinical study[J]. J Clin Psychopharmacol,2011, 31(1):98.
[17] TINI E, SMIGIELSKI L, ROMANOS M, et al. Therapeutic drug monitoring of sertraline in children and adolescents:a naturalistic study with insights into the clinical response and treatment of obsessive-compulsive disorder[J]. Compr Psychiatry, 2022, 115:152301.
[18]任丽娜,叶兰仙,张玉堂. SSRIs类剂量、浓度与抗抑郁疗效的关系[J].实用药物与临床, 2017, 20(8):972.
[19]熊玉卿,殷嫦嫦,张会杰,等.舍曲林在中国健康志愿者体内的药代动力学研究[J].中国药理学通报, 2006, 22(5):616.
[20]吴海根,王珍姝,胡敏仪,等.基于治疗药物监测的舍曲林血药浓度结果及其影响因素分析[J].广东药科大学学报, 2022, 38(6):64.
[21] LUNDMARK J, REIS M, BENGTSSON F. Therapeutic drug monitoring of sertraline:variability factors as displayed in a clinical setting[J]. Ther Drug Monit, 2000, 22(4):446.
[22]刘舒静,李晓琳,黄善情,等.舍曲林在青少年抑郁症患者中剂量校正浓度影响因素分析[J].中国临床药理学杂志, 2021,37(22):3060.
[23] FU R, HAO X, YU J, et al. Machine learning-based prediction of sertraline concentration in patients with depression through therapeutic drug monitoring[J]. Front Pharmacol, 2024, 15:1289673.
[24]郭俊峰,朱文佳.抑郁症患者采用舍曲林治疗血药浓度影响因素分析[J].新疆医学, 2024, 54(9):108.
[25]兰春.舍曲林所致不良反应近况文献概述[J].中国药物滥用防治杂志, 2017, 23(3):180.
[26] GAEBLER A J, HAEN E, OMAR N B, et al. Lower sertraline plasma concentration in patients co-medicated with clozapineImplications for pharmacological augmentation strategies in schizophrenia[J]. Pharmacol Res Perspect, 2023, 11(2):e01065.
[27] GAEBLER A J, SCHORETSANITIS G, BEN OMAR N, et al.Metamizole but not ibuprofen reduces the plasma concentration of sertraline:Implications for the concurrent treatment of pain and depression/anxiety disorders[J]. Br J Clin Pharmacol, 2021,87(3):1111.
[28] SAIZ-RODRíGUEZ M, BELMONTE C, ROMáN M, et al. Effect of polymorphisms on the pharmacokinetics, pharmacodynamics and safety of sertraline in healthy volunteers[J]. Basic Clin Pharmacol Toxicol, 2018, 122(5):501.
[29] AKAMINE Y, YASUI-FURUKORI N, IEIRI I, et al. Psychotropic drug-drug interactions involving P-glycoprotein[J]. CNS Drugs,2012, 26(11):959.
[30] BR?TEN L S, HASLEMO T, JUKIC M M, et al. Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients[J]. Neuropsychopharmacology, 2020, 45(3):570.
[31] JOHNSON-DAVIS K L, DOYLE K. Therapeutic drug monitoring in pregnant patients[J]. Ther Drug Monit, 2020, 42(2):172.
[32] HEINONEN E, BLENNOW M, BLOMDAHL-WETTERHOLM M,et al. Sertraline concentrations in pregnant women are steady and the drug transfer to their infants is low[J]. Eur J Clin Pharmacol,2021, 77(9):1323.
[33] LEUTRITZ A L, VAN BRAAM L, PREIS K, et al. Psychotropic medication in pregnancy and lactation and early development of exposed children[J]. Br J Clin Pharmacol, 2023, 89(2):737.
[34] STIKA C S, WISNER K L, GEORGE A L Jr, et al. Changes in sertraline plasma concentrations across pregnancy and postpartum[J]. Clin Pharmacol Ther, 2023, 112(6):1280.
[35] MONFORT A, CARDOSO E, EAP C B, et al. A population pharmacokinetic model for sertraline in women during the perinatal period-A contribution from the ConcePTION project[J]. Br J Clin Pharmacol, 2024, 90(11):2849.
[36] MOREIRA F L, BENZI J R L, PINTO L, et al. Optimizing therapeutic drug monitoring in pregnant women:a critical literature review[J]. Ther Drug Monit, 2023, 45(2):159.
[37]谭亚倩,陈紫琦,刘舒静,等.基于治疗药物监测的舍曲林在抑郁症患者中血药浓度/剂量比的影响因素分析[J].中国医院用药评价与分析, 2021, 21(6):698.
[38]蔡雪梅,胡大春. CYP2C19遗传多态性与药物代谢及疗效的研究进展[J].当代医学, 2012, 18(16):21
[39] UNTERECKER S, RIEDERER P, PROFT F, et al. Effects of gender and age on serum concentrations of antidepressants under naturalistic conditions[J]. J Neural Transm(Vienna), 2013,120(8):1237.
基本信息:
DOI：10.19577/j.1007-4406.2025.06.015
中图分类号:R969.1
引用信息:
[1]自雪梅,王晶晶.舍曲林血药浓度影响因素研究进展[J].中国临床药学杂志,2025,34(06):476-480.DOI:10.19577/j.1007-4406.2025.06.015.
基金信息:
国家自然科学基金（编号82460737）;云南省应用基础研究-昆明医科大学联合专项（编号202401AY070001-034）
2025-06-25
2025-06-25